UArizona researchers develop ' Goldilocks drug ' to treat triple-negative breast cancer

UArizona researchers develop'Goldilocks drug' to treat triple-negative breast cancerUniversity of Arizona researchers have been working for decades to develop a drug that so specifically targets a deadly kind of breast cancer that there are little to no toxic side effects. Mikayla Mace Kelley Today University Communicationstest tubes.jpgHealthScience and TechnologyBIO5Cancer CenterCollege of ScienceExpertsResearchScienceTech Launch Arizona Media contact(s)Mikayla Mace Kelley Science Writer, University Communicationsmikaylamace@arizona.edu520-621-1878 Researcher contact(s)Joyce Schroeder Molecular and Cellular Biologyjoyces@arizona.edu520-626-1384After decades of research and two previous drug development attempts, things are looking promising for a team of University of Arizona researchers working on a less toxic treatment for a specific type of breast cancer.The researchers have developed a drug compound that appears to stop cancer cell growth in what ' s known as triple-negative breast cancer. The drug, which has not yet been tested in humans, has been shown to eliminate tumors in mice, with little to no effect on normal healthy cells, making it potentially nontoxic for patients.The therapy is based on a newly discovered way that a gene known as epidermal growth factor receptor, or EGFR, leads to cancer. EGFR is a long-investigated oncogene – a gene that in certain circumstances can transform a cell into a tumor cell.schroeder.jpg Joyce SchroederThe ...
Source: The University of Arizona: Health - Category: Universities & Medical Training Authors: Source Type: research